You are here

  • Home
  • Archive
  • Volume 9, Issue 6
  • Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial

 

Online download statistics by month:

Online download statistics by month: June 2021 to October 2024

AbstractFullPdf
Jun 2021499500195
Jul 202127827868
Aug 202119919969
Sep 202126726763
Oct 202116416487
Nov 202113113153
Dec 202112812856
Jan 202210410729
Feb 2022919760
Mar 2022929369
Apr 202213914044
May 202212413054
Jun 202213714687
Jul 202210610946
Aug 202214014349
Sep 202212413154
Oct 202214314769
Nov 202218418460
Dec 202212212734
Jan 202316016234
Feb 202313914283
Mar 202315315364
Apr 202310310443
May 202310110149
Jun 202313113249
Jul 2023969631
Aug 202312012360
Sep 202311111128
Oct 202313413455
Nov 202315015129
Dec 202317517665
Jan 20248182140
Feb 202415115144
Mar 2024102103102
Apr 202410610757
May 2024585929
Jun 202411011452
Jul 202410610727
Aug 202410110162
Sep 202411211456
Oct 202414315156
Total581558952461